

The University of Maine

DigitalCommons@UMaine

Health & Public Safety

Margaret Chase Smith Policy Center

7-29-2021

Maine Naloxone Distribution Initiative: Project-To-Date Totals through June 30, 2021

Margaret Chase Smith Policy Center

Follow this and additional works at: https://digitalcommons.library.umaine.edu/mcspc_healthsafety

This Report is brought to you for free and open access by DigitalCommons@UMaine. It has been accepted for inclusion in Health & Public Safety by an authorized administrator of DigitalCommons@UMaine. For more information, please contact um.library.technical.services@maine.edu.

Maine Naloxone Distribution Initiative

Project-To-Date Totals through June 30, 2021

Prepared by the Margaret Chase Smith Policy Center
University of Maine

In July 2019, the Maine Naloxone Distribution Initiative (MNDI) launched an overdose education, prevention, and naloxone distribution project. Public health and harm reduction partners, known as Tier 1 Distributors, began distributing state-supplied naloxone rescue kits across Maine to clinicians, community partners, and end users. This brief provides information on naloxone distribution and reported overdose reversals by the Tier 1 organizations comprising the MNDI from the initiation of the project through June 2021, with a particular emphasis on the second quarter of 2021.

Tier 1 organizations include Bangor Public Health (BPH), Portland Public Health (PPH), MaineGeneral Health (MG), and Maine Access Points (MAP). BPH serves the Aroostook, Downeast, and Penquis public health districts, PPH serves Cumberland and York, and MG serves Central, Midcoast, and Western. MAP distributes naloxone statewide with a particular focus on rural regions. Data from the Office of the Attorney General’s (OAG) law enforcement administered naloxone program have also been included to provide an overview of the combined public health, harm reduction, and public safety efforts in Maine.

Fatal drug overdoses increased in 2020 and that trend has continued in the second quarter of 2021. Currently, there is no comprehensive way to fully enumerate the total of nonfatal overdoses as this metric relies on voluntary reporting. Thus, it is difficult to quantify the full efficacy of naloxone distribution efforts during this troubling period. The distribution and reported reversal data tables and figure in this report offer conservative estimates of the lives saved through public health, harm reduction, and safety efforts, which prevented the number of drug deaths from potentially being much higher.

Additional resources, data, and visualizations are available at the Maine Drug Data Hub: <https://mainedrugdata.org/>.




Figure 1: Number of naloxone doses distributed by the Maine Naloxone Distribution Initiative from April through June 2021

Public Health—Tier 1 Distributors

During the second quarter of 2021 (April–June):

- 18,290 doses of naloxone have been distributed
- 426 overdose reversals have been voluntarily reported.

From July 2019 through June 2021 (MNDI project-to-date totals):

- 94,670 doses of naloxone have been distributed
- 2118 overdose reversals have been voluntarily reported.

Public Safety—Law Enforcement Agencies

During the second quarter of 2021 (April–June):

- 1220 doses of naloxone have been distributed
- 73 overdose reversals have been voluntarily reported.

From July 2019 through June 2021:

- 9172 doses of naloxone have been distributed
- 444 overdose reversals have been voluntarily reported.

Table 1 Doses of naloxone distributed by Tier 1 distributors and OAG

	2019	2020	JAN 2021	FEB 2021	MAR 2021	APR 2021	MAY 2021	JUNE 2021	TOTAL
BPH	1768	10,550	732	224	516	1112	700	2442	18,044
PPH	3792	8640	96	292	1704	430	690	872	16,516
MG	2550	5870	2032	784	1622	898	878	1380	16,014
MAP (IM)	3486	19,561	2216	2834	1888	1874	2552	2676	37,087
MAP (IN)	510	3599	410	392	494	354	656	776	7191
OAG	2034	3914	852	288	864	412	516	292	9172
TOTAL	14,140	52,134	6338	4814	7088	5080	5992	8438	104,024

Notes: (1) Unit is doses for all values. (2) IM = intramuscular; IN = intranasal. All values are IN unless otherwise indicated. (3) MAP distribution initially included state-supplied and nonstate-supplied naloxone. (4) 2019 data is for July through December only. (5) A revision has been made to BPH March 2021 and PPH April 2021

Table 2 Number of overdose reversals voluntarily reported to Tier 1 distributors (by individuals or Tier 2 distributors) and overdose reversals reported by OAG law enforcement agencies

	2019	2020	JAN 2021	FEB 2021	MAR 2021	APR 2021	MAY 2021	JUNE 2021	TOTAL
BPH	17	289	49	55	93	36	47	68	654
PPH	28	304	4	-	10	28	20	6	397
MG	1	87	10	7	15	19	18	29	186
MAP	29	521	64	38	38	56	15	86	847
OAG	50	271	26	10	14	15	32	26	444
OD-ME app	-	31	0	0	2	0	1	0	34
TOTAL	125	1503	153	110	172	154	133	215	2562

Notes: (1) Reversal totals are conservative estimates as not all reversals are reported. (2) OD-ME app is a mobile phone app developed in 2020 to support naloxone administration. (3) Overdose reversal figures may increase as backdated Tier 2 distributor and OAG incident reports are received. (4) 2019 data is July through December only.